Braeburn

Braeburn Inc. is a pharmaceutical company focused on developing and commercializing medications for serious central nervous system disorders, particularly opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn aims to transform the management of opioid use disorder (OUD) through innovative treatment solutions. Its lead product, BRIXADI, offers extended-release weekly and monthly injectable formulations of buprenorphine, specifically designed for the treatment of moderate to severe OUD. The company is dedicated to providing individualized dosing regimens and delivery options to better address the growing challenges posed by addiction, thereby improving care for those affected by this chronic condition. Braeburn partners with the community to ensure that individuals with OUD receive effective treatment and have the opportunity to realize their full potential.